Nichts neues, aber zumindest wird Calypte in diesem Newsletter regelmäßig erwähnt.
"Calypte Biomedical Corporation (OTCBB: CYPT), the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, announced this week that it had shipped an order of 150,000 HIV-1 EIA tests to its Chinese distributor, Zhong Yang Pute Co. The order, originally announced in June, had been delayed due to the disruption of normal deliveries to China created by SARS. The company had previously announced that it had received a $2.5 million investment from Marr Technologies Limited, as part of a Memorandum of Understanding, regarding the formation of a joint venture in China. The intent is to create a platform for distribution and sale of Calypte's products there. The stock rallied 21.6% this week, as it appears from the volume that the conversions from a previously completed financing have at least temporarily stopped, which should allow the stock to rally further on positive developments. It ended the week at $0.146."
|